Autolus Therapeutics (AUTL) Tax Provisions (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Tax Provisions data on file, last reported at -$1.2 million in Q4 2025.

• Quarterly Tax Provisions fell 179.0% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (up 30.91% YoY) and the FY2025 annual result came in at $2.0 million, up 30.89% from the prior year.
• Tax Provisions slipped to -$1.2 million in Q4 2025, from $532000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $19.6 million in Q4 2022 to a low of -$6.4 million in Q2 2021.
• A 5-year average of $1.2 million and a median of -$6500.0 in 2022 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2023 — Tax Provisions plunged 320.0% — and 2025, when it surged 27912.5%.
• Tracing AUTL's Tax Provisions over 5 years: stood at $17.6 million in 2021, then increased by 11.29% to $19.6 million in 2022, then plunged by 100.12% to -$24000.0 in 2023, then surged by 6191.67% to $1.5 million in 2024, then sank by 179.0% to -$1.2 million in 2025.
• The last three Tax Provisions figures came in at -$1.2 million (Q4 2025), $532000.0 (Q3 2025), and $397000.0 (Q2 2025), per Business Quant data.